Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib Plus Chemotherapy vs Icotinib Monotherapy in EGFR-Mutated NSCLC
NCT03151161Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2015
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of icotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Response Evaluation Criteria in Solid Tumors 1.1 at 8 weeks. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03151161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03151161.